CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Cyproterone acetate/ethinylestradiol (CPA/EE) +1 moredrug
Likely dose
Cyproterone acetate/ethinylestradiol (CPA/EE) 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02729545
NCT02729545Phase 2Completed
CompareCT.gov

The Efficacy and Safety Study of Tung's Acupuncture for Improving Ovarian Function of Polycystic Ovarian Syndrome: a Randomised Controlled Trial

Beijing Hospital of Integrated Traditional Chinese and Western Medicine·interventional·Posted Apr 6, 2016·Updated Oct 8, 2019

In Brief

A Phase 2 clinical trial evaluating Tung's acupuncture and Cyproterone acetate/ethinylestradiol (CPA/EE) for Polycystic Ovarian Syndrome. Completed, enrolled 60 participants across 1 site.

Detailed Summary

This study evaluates the efficacy and safety in improving ovarian function of polycystic ovarian syndrome in adults. Half of patients will receive Tung's acupuncture therapy, while the other half will receive Diane-35(CPA/EE) as the control group.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolycystic Ovarian Syndrome
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 6, 2016
Enrollment StartApr 1, 2016
Primary CompletionMar 1, 2018
Study CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.2 years ago

Interventions

Tung's acupunctureother

The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).

Cyproterone acetate/ethinylestradiol (CPA/EE)drug

Cyproterone acetate/ethinylestradiol (CPA/EE) contains 2mg cyproterone acetate (an anti-androgenic progestin) and 0.035mg ethinylestradiol (CPA/EE). The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).